Metropolitan Life Insurance Company (MetLife)’s Cytek Biosciences CTKB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,522	Closed	-$43.8K	–	526
2024 Q1	$43.8K	Sell	6,522 -967	-13%	-$7.65K	﹤0.01%	1476
2023 Q4	$68.3K	Hold	7,489	–	–	﹤0.01%	1279
2023 Q3	$41.3K	Buy	7,489 +793	+12%	+$6.36K	﹤0.01%	1514
2023 Q2	$57.2K	Buy	6,696 +405	+6%	+$3.63K	﹤0.01%	1346
2023 Q1	$57.8K	Sell	6,291 -792	-11%	-$8.52K	﹤0.01%	1311
2022 Q4	$72.3K	Hold	7,083	–	–	﹤0.01%	1248
2022 Q3	$104K	Hold	7,083	–	–	﹤0.01%	993
2022 Q2	$76K	Buy	7,083 +668	+10%	+$6.65K	﹤0.01%	1229
2022 Q1	$69.2K	Buy	6,415 +1,536	+31%	+$20.7K	﹤0.01%	1410
2021 Q4	$79.6K	Hold	4,879	–	–	﹤0.01%	2593
2021 Q3	$104K	Buy	+4,879	New	+$115K	﹤0.01%	2494

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CTKB Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cytek Biosciences (CTKB) in Q2 2024, closing a stake of 6,522 shares — an estimated $43.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CTKB in Q3 2021 and held it in 11 quarters. The position peaked at $104K in Q3 2021. 128 funds tracked by Wall St. Rank hold CTKB as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Cytek Biosciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,522 Cytek Biosciences shares in Q2 2024, an estimated $43.8K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Cytek Biosciences in Q3 2021 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s Cytek Biosciences position peaked at $104K in Q3 2021.
128 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.